Table 1

Baseline characteristics

VariableLevelOverall population (n=398)Patients who developed severe cytopenia (n=48)
Year of CAR-T therapyMedian (min–max)
(IQR)
2020 (2018–2021)
(2019–2020)
2019 (2018–2021)
(2019–2020)
Previous transplantationNo previous transplant295 (74.1%)36 (75%)
Previous transplant10. (25.9%)12 (25%)
*Disease status at time of CAR-T therapyCR/PR58 (14.6%)7 (14.6%)
No CR/PR339 (85.4%)41 (86%)
Missing10
Patient age (years)Median (min–max)
(IQR)
61.4 (18.7–81)
(52.9–69.5)
64.3 (25.2–80.2)
(52.6–70.4)
Patient sexMale243 (61.1%)32 (66.7%)
Female155 (38.9%)16 (33.3%)
Karnofsky score≥90197 (62.3%)23 (63.9%)
<90119 (37.7%)13 (36.1%)
Missing8212
CAR T-cell productAxicel245 (61.6%)36 (75%)
Tisacel153 (38.4%)12 (25%)
Total number of treatment lines before CAR-T infusion139 (10.5%)4 (8.5%)
2108 (29%)8 (17%)
≥2 (not specified)1 (0.3%)0 (0%)
3131 (35.2%)22 (46.8%)
≥3 (not specified)10 (2.7%)0 (0%)
441 (11%)6 (12.8%)
524 (6.5%)5 (10.6%)
611 (3%)1 (2.1%)
75 (1.3%)1 (2.1%)
82 (0.5%)0 (0%)
Missing261
Type of lymphodepletionFludarabine–cyclophosphamide393 (99%)48 (100%)
†Other4 (1%)0 (0%)
Missing10
Time between diagnosis and CAR-T≤1 year137 (34.4%)22 (45.8%)
>1 year261 (65.6%)26 (54.2%)
  • *The disease status given is directly at CAR-T therapy meaning after bridging therapy or after watch and wait during the CAR-T production period.

  • †Other (4) = 1 cyclophosphamide, 1 bendamustine, 1 fludarabine, 1 fludarabine+bendamustine.

  • CAR, chimeric antigen receptor; CR, complete remission; PR, partial remission.